Predicate |
Object |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2866 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
filingDate |
2006-11-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate |
2009-05-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
JP-WO2007061029-A1 |
titleOfInvention |
Prostate cancer treatment |
abstract |
The present inventors examined the antitumor effect of anti-IL-6 receptor antibody on prostate cancer. As a result, it was revealed that the anti-IL-6 receptor antibody exhibits an antitumor effect against prostate cancer both in vivo and in vitro. It was also revealed that hPM1 exhibits an antitumor effect via the IL-6 receptor. |
priorityDate |
2005-11-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |